Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy
AbstractChemotherapy-Induced Peripheral Neuropathy (CIPN) is a dose-limiting side effect of several antineoplastic drugs which significantly reduces patients’ quality of life. Although different molecular mechanisms have been investigated, CIPN pathobiology has not been clarified yet. It has largely been recognized that Dorsal Root Ganglia are the main targets of chemotherapy and that the longest nerves are the most damaged, together with fast axonal transport. Indeed, this bidirectional cargo-specific transport has a pivotal role in neuronal function and its impairment is involved in several neurodegenerative and neurodevelopmental diseases. Literature data demonstrate that, despite different mechanisms of action, all antineoplastic agents impair the axonal trafficking to some extent and the severity of the neuropathy correlates with the degree of damage on this bidirectional transport. In this paper, we will examine the effect of the main old and new chemotherapeutic drug categories on axonal transport, with the aim of clarifying their potential mechanisms of action, and, if possible, of identifying neuroprotective strategies, based on the knowledge of the alterations induced by each drugs. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Nicolini, G.; Monfrini, M.; Scuteri, A. Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy. Toxics 2015, 3, 322-341.
Nicolini G, Monfrini M, Scuteri A. Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy. Toxics. 2015; 3(3):322-341.Chicago/Turabian Style
Nicolini, Gabriella; Monfrini, Marianna; Scuteri, Arianna. 2015. "Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy." Toxics 3, no. 3: 322-341.